After Brexit, UK pharma is striving to reinvigorate drug discovery through collaboration. This infographic shows why that’s necessary.
A new report from the Association of the British Pharmaceutical Industry (ABPI) has a grim finding: the UK is beginning to lose out on global drug discovery investment compared to 10 years ago. Spending on pharmaceutical R&D in Britain has increased to £4Bn per year, but this rate is not enough to keep up with the global pace.
Consequently, the industry is shifting to focus on collaboration and open innovation, as “60% of major pharmaceutical companies have increased investment in outsourced and collaborative drug discovery work in the UK over the last 10 years, whilst simultaneously decreasing the number of in-house drug discovery lab staff,” according to the report.
Biotech stands to be one of the main beneficiaries of this new collaboration-driven model as one of the best pools of potential partners for pharma.
Featured Image: imagedb.com/shutterstock.com